Calliditas Therapeutics AB (NAS:CALT)
$ 40.0001 -0.1599 (-0.4%) Market Cap: 1.08 Bil Enterprise Value: 1.10 Bil PE Ratio: 0 PB Ratio: 104.30 GF Score: 35/100

Q3 2022 Calliditas Therapeutics AB Earnings Call Transcript

Nov 14, 2022 / 01:00PM GMT
Release Date Price: $15 (-1.64%)
Operator

Welcome to Calliditas Therapeutics Quarter 3 Presentation 2022.

(Operator Instructions)

I will now hand over the word to CEO, Renee Aguiar-Lucander, please begin the meeting.

Renee Aguiar;Lucander;publ;CEO
Calliditas Therapeutics AB

()-

Thank you very much, and welcome, everybody, to the Q3 report. With me on today's call, I have Fredrik Johansson, our Chief Financial Officer; Richard Philipson, Chief Medical Officer; and Mr. Andrew Udell, President of North America. So if you go to Page 2, please. I'd like to draw your attention to the disclaimer page related to forward-looking statements and refer you to the company's reports and other filings including those filings which contain risk factors and other relevant information.

So if we turn to Page 3, please. So some of the Q3 highlights. So in this quarter, Calliditas has achieved another major milestone as we received formal conditional approval of Kinpeygo in Europe. Subsequent to achieving this, we immediately started the transfer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot